Lilly’s orforglipron is the first oral obesity therapy to show its worth in the maintenance setting
Lilly’s orforglipron is the first oral obesity therapy to show its worth in the maintenance setting
Body unavailable. Use the original source.
Lilly’s orforglipron is the first oral obesity therapy to show its worth in the maintenance setting
A compact weekly email covering company moves, product signals, regulatory updates, and notable funding.